Recent experience
Paraguay · 2026
A biotech company with a regional footprint needed to know whom to talk to and where to start. We mapped the genetics, hemato-oncology and oncology centers, the opinion leaders in each area, and the coverage and purchasing routes for specialty products. With that, the company set its entry plan and its first contacts.
Uruguay · 2025
A pharmaceutical company was considering entering with products from a manufacturing plant in India, across several therapeutic areas, and had to decide where to start. We ranked the areas by revenue and patients, analyzed the competition and reviewed the registration requirements for each product. The result was the launch sequence.
Argentina · 2026 · Kovaris research
Using public sources, we reconstructed what happened to the price of icatibant when a second brand entered and then left the market, and what it shows about how a high-cost treatment is purchased and how its price is defended in Argentina. Published as a white paper in October 2026.
Clients and details anonymized for confidentiality. The 2025 case comes from the founder's work before Kovaris.
More than 50 projects for pharma and biotech in Latin America, Europe and the United States as Principal Consultant at a pharma-focused consultancy (2016 to 2024) and as a consultant at IQVIA for the Southern Cone (2014 to 2016), in strategy, market intelligence, pricing and access, presented to general managers, business unit heads and global brand teams.
A 30-minute call is enough to define the question, the package and the delivery date.